Petra Janovska

Petra Janovska

Auto-generated profile, based on publicly available information

Petra Janovska

Laboratory of Adipose Tissue Biology, Institute of Physiology of the Czech Academy of Sciences, Prague, Czech republic

Research Focus & Metrics

Academic Career Length

31Years (1996-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 June 2016 in Diabetes
Verified
Journal Article
Open access
PDF file
OKOndrej Kuda
Ondrej Kuda
MBMarie Brezinova
Marie Brezinova
MRMartina Rombaldova
Martina Rombaldova
BSBarbora Slavikova
Barbora Slavikova
MPMartin Posta
Martin Posta
JKJr. Jan Kopecky
Jr. Jan Kopecky
White adipose tissue (WAT) is a complex organ with both metabolic and endocrine functions. Dysregulation of all of these functions of WAT, together with low-grade inflammation of the tissue in obese individuals, contributes to the development of insulin resistance and type 2 diabetes. n-3 polyunsaturated fatty acids (PUFAs) of marine origin play an important role in the resolution of inflammation and exert beneficial metabolic effects. Using experiments in mice and overweight/obese patients with type 2 diabetes, we elucidated the structures of novel members of fatty acid esters of hydroxy fatty acids—lipokines derived from docosahexaenoic acid (DHA) and linoleic acid, which were present in serum and WAT after n-3 PUFA supplementation. These compounds contained DHA esterified to 9- and 13-hydroxyoctadecadienoic acid (HLA) or 14-hydroxydocosahexaenoic acid (HDHA), termed 9-DHAHLA, 13-DHAHLA, and 14-DHAHDHA, and were synthesized by adipocytes at concentrations comparable to those of protectins and resolvins derived from DHA in WAT. 13-DHAHLA exerted anti-inflammatory and proresolving properties while reducing macrophage activation by lipopolysaccharides and enhancing the phagocytosis of zymosan particles. Our results document the existence of novel lipid mediators, which are involved in the beneficial anti-inflammatory effects attributed to n-3 PUFAs, in both mice and humans.

3 May 2011 in International Journal of Obesity
Verified
Journal Article
Closed access
DMD Medrikova
D Medrikova
ZJZuzana Macek Jilkova
Zuzana Macek Jilkova
Kristina BardovaKristina Bardova
Kristina Bardova
PJP Janovska
P Janovska
MRM Rossmeisl
M Rossmeisl
JKJan Kopecky
Jan Kopecky

29 August 2016 in Nature Medicine
Verified
Journal Article
Closed access
MRMaria Rohm
Maria Rohm
MSMichaela Schäfer
Michaela Schäfer
VLVictor Laurent
Victor Laurent
BÜBilgen Ekim Üstünel
Bilgen Ekim Üstünel
KNKatharina Niopek
Katharina Niopek
SHStephan Herzig
Stephan Herzig

11 March 2009 in Diabetologia
Verified
Journal Article
Closed access
PDF file
OKOndrej Kuda
Ondrej Kuda
TJT. Jelenik
T. Jelenik
ZJZuzana Macek Jilkova
Zuzana Macek Jilkova
PFP. Flachs
P. Flachs
MRM. Rossmeisl
M. Rossmeisl
JKJan Kopecky
Jan Kopecky

16 April 2019 in Scientific Reports
Verified
Journal Article
Open access
PDF file
OHOlga Horakova
Olga Horakova
PKPetra Kroupova
Petra Kroupova
Kristina BardovaKristina Bardova
Kristina Bardova
JBJana Buresova
Jana Buresova
PJPetra Janovska
Petra Janovska
MRMartin Rossmeisl
Martin Rossmeisl
Metformin is currently the most prescribed drug for treatment of type 2 diabetes mellitus in humans. It has been well established that long-term treatment with metformin improves glucose tolerance in mice by inhibiting hepatic gluconeogenesis. Interestingly, a single dose of orally administered metformin acutely lowers blood glucose levels, however, little is known about the mechanism involved in this effect. Glucose tolerance, as assessed by the glucose tolerance test, was improved in response to prior oral metformin administration when compared to vehicle-treated mice, irrespective of whether the animals were fed either the standard or high-fat diet. Blood glucose-lowering effects of acutely administered metformin were also observed in mice lacking functional AMP-activated protein kinase, and were independent of glucagon-like-peptide-1 or N-methyl-D-aspartate receptors signaling. [18F]-FDG/PET revealed a slower intestinal transit of labeled glucose after metformin as compared to vehicle administration. Finally, metformin in a dose-dependent but indirect manner decreased glucose transport from the intestinal lumen into the blood, which was observed ex vivo as well as in vivo. Our results support the view that the inhibition of transepithelial glucose transport in the intestine is responsible for lowering blood glucose levels during an early response to oral administration of metformin.

21 July 2011 in Diabetologia
Verified
Journal Article
Closed access
PDF file
PFP. Flachs
P. Flachs
RRR. Rühl
R. Rühl
MHM. Hensler
M. Hensler
PJP. Janovska
P. Janovska
PZPetr Zouhar
Petr Zouhar
JKJan Kopecky
Jan Kopecky